title: Long-term administration of vasopressin can cause Ménière's disease in mice.
abstract: CONCLUSIONS
  A new murine model of Ménière's disease has been developed, based on long-term administration of vasopressin. Induction of vestibular dysfunction in the present animal model can cause additional stress, by reducing inner ear blood flow. Latanoprost, a selective agonist for the FP prostanoid receptor, may become a new remedy for Ménière's disease.
  
  
  OBJECTIVE
  The purpose of this study was to develop a more suitable animal model, with a closer resemblance to the pathophysiological process in Ménière's disease.
  
  
  METHODS
  Adult CBA/J or ICR mice were treated by subcutaneous injection of vasopressin for 5 days up to 8 weeks. Morphological analyses were performed of the cochlea, vestibular end organs and endolymphatic sac. The effect of latanoprost on the development of endolymphatic hydrops was also examined.
  
  
  RESULTS
  All experimental animals showed mild to moderate endolymphatic hydrops, increasing in severity as the vasopressin treatment was prolonged. Animals treated with vasopressin for 8 weeks showed severe endolymphatic hydrops with partial loss of outer hair cells and spiral ganglion cells. These animals also had a reversible vestibular dysfunction following intratympanic injection of epinephrine. Latanoprost inhibited the development of endolymphatic hydrops caused by vasopressin.
authors.affiliation: Department of Otolaryngology, Hiroshima University Faculty of Medicine , Hiroshima , Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Katagiri
authors.forename: Masaya
authors.initials: M
authors.lastname: Takumida
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Hirakawa
authors.forename: Matti
authors.initials: M
authors.lastname: Anniko
mesh_terms: D000818:Animals; D001707:Biopsy, Needle; D003051:Cochlea / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004712:Endolymphatic Sac / Q000187:drug effects / Q000473:pathology; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D000077338:Latanoprost; D008575:Meniere Disease / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D008808:Mice, Inbred CBA; D008813:Mice, Inbred ICR; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology; D011897:Random Allocation; D012016:Reference Values; D018570:Risk Assessment; D013997:Time Factors; D014667:Vasopressins / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D011461:Prostaglandins F, Synthetic; D014667:Vasopressins; D000077338:Latanoprost
keywords: Endolymphatic hydrops; latanoprost; vestibular dysfunction